CING Cingulate
- 0.6611
- -0.0318-4.59%
- 0.6650
- +0.0039+0.59%
Cingulate News
Express News | Cingulate Inc - Notified That Panel of Nasdaq Determined That Co Has Regained Compliance With Minimum Stockholders' Equity Rule
Maxim Group Maintains Cingulate(CING.US) With Hold Rating
Maxim Group analyst Naz Rahman maintains $Cingulate(CING.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 29.6% and a total average return of -12.6% over the past
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cingulate Inc (CING), Indaptus Therapeutics (INDP) and Immunocore Holdings (IMCR)
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersSharps Technology (NASDAQ:STSS) stock increased by 56.5% to $0.4 during Wednesday's after-market session. The market value of their outstanding shares is at $6.3 million. Geovax Labs (NASDAQ:GO
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersMustang Bio (NASDAQ:MBIO) stock increased by 51.6% to $0.47 during Wednesday's pre-market session. The market value of their outstanding shares is at $5.8 million. NeuroBo Pharmaceuticals (NASD
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersRezolute (NASDAQ:RZLT) stock increased by 52.7% to $4.58 during Tuesday's after-market session. The company's market cap stands at $183.8 million. The company's, Q3 earnings came out 4 days ago
Express News | Cingulate Inc: Cingulate Has Begun Nda Preparation and Expects to Submit Its Filing in First Half of 2025
Express News | Cingulate Inc: Advancing Discussions With Commercialization Partners
Express News | FDA Clears Cingulate to File for Marketing Approval of Ctx-1301 in the Treatment of Adhd
Express News | Cingulate Files Prospectus Related to Offer, Resale of up to 2 Mln Shares of Common Stock by Lincoln Park Capital Fund, LLC - SEC Filing
Analysts Conflicted on These Healthcare Names: Cingulate Inc (CING) and Genenta Science SpA Sponsored ADR (GNTA)
Express News | As Of March 31, 2024, Cingulate Had $1.1M In Cash And Cash Equivalents. Management Intends To Seek Opportunities To Access Additional Capital As Needed
Cingulate Q4 2023 GAAP EPS $(0.60) May Not Be Comparable To $(4.86) Estimate
Cingulate Q4 2023 GAAP EPS $(0.60) May Not Be Comparable To $(4.86) Estimate
10-Q: Quarterly report
Express News | Cingulate Inc - Ctx-1301 on Track to File for Marketing Approval With FDA in 1H 2025
Express News | Cingulate Inc - Increase of $10 Mln in Stockholders' Equity
Cingulate 1Q Loss/Shr 60c >CINGW
Cingulate 1Q Loss/Shr 60c >CINGW
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
CTx-1301 on track to file for Marketing Approval with FDA in 1H 2025 Increase of $10 Million in Stockholders' Equity KANSAS CITY, Kan., May 08, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a
Press Release: Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update CTx-1301 on track to file for Marketing Approval with FDA in 1H 2025 Increase of $10 Million in Stock
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to Be Featured With Chairman and CEO Shane J. Schaffer on Benzinga All Live Access
KANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology
Analysis
Price Target
No Data
